233 related articles for article (PubMed ID: 18832004)
1. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
Vaccine; 2008 Nov; 26(50):6329-37. PubMed ID: 18832004
[TBL] [Abstract][Full Text] [Related]
2. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
4. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
5. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
Palin A; Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
Vaccine; 2007 Jan; 25(4):741-50. PubMed ID: 16959385
[TBL] [Abstract][Full Text] [Related]
6. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
[TBL] [Abstract][Full Text] [Related]
7. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
8. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
[TBL] [Abstract][Full Text] [Related]
9. Oral vaccination with different antigens from Yersinia pestis KIM delivered by live attenuated Salmonella typhimurium elicits a protective immune response against plague.
Branger CG; Fetherston JD; Perry RD; Curtiss R
Adv Exp Med Biol; 2007; 603():387-99. PubMed ID: 17966435
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.
DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O
Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated Salmonella as a vaccine against bubonic and pneumonic Yersinia pestis challenge.
Branger CG; Sun W; Torres-Escobar A; Perry R; Roland KL; Fetherston J; Curtiss R
Vaccine; 2010 Dec; 29(2):274-82. PubMed ID: 20979987
[TBL] [Abstract][Full Text] [Related]
12. Different strategies for preparation of non-tagged rV270 protein and its efficacy against Yersinia pestis challenge.
Wang W; Qi ZZ; Zhang QW; Wu BC; Zhu ZW; Yang YH; Cui BZ; Dai RX; Qiu YF; Wang ZY; Guo ZB; Shi TX; Wang H; Yang RF; Wang XY
Biomed Environ Sci; 2010 Oct; 23(5):333-40. PubMed ID: 21112480
[TBL] [Abstract][Full Text] [Related]
13. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.
Sanapala S; Rahav H; Patel H; Sun W; Curtiss R
Vaccine; 2016 May; 34(21):2410-2416. PubMed ID: 27060051
[TBL] [Abstract][Full Text] [Related]
14. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
[TBL] [Abstract][Full Text] [Related]
16. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
[TBL] [Abstract][Full Text] [Related]
17. Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis.
Bhattacharya D; Mecsas J; Hu LT
Vaccine; 2010 Nov; 28(48):7683-9. PubMed ID: 20875494
[TBL] [Abstract][Full Text] [Related]
18. Yersinia pestis YadC: a novel vaccine candidate against plague.
Murphy BS; Wulff CR; Garvy BA; Straley SC
Adv Exp Med Biol; 2007; 603():400-14. PubMed ID: 17966436
[TBL] [Abstract][Full Text] [Related]
19. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
